Protein degrader approval offers hope to relapsed multiple myeloma patients

Following impressive early results, the US Food and Drug Administration (FDA) has approved the first example of what Bristol Myers Squibb (BMS) calls the CELMoD class of molecular glues. The FDA gave accelerated approval to iberdomide (Zenbexus) in a combination therapy including anti-cancer monoclonal antibody daratumumab, for use when multiple myeloma patients stop responding to prior treatments.